Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

9.530 -0.010 (-0.10%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
Via Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
Via Investor Brand Network
Exposures Product Safety
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024
CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
Via Investor Brand Network
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Cybin Inc.
Via Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace
Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
Via AB Newswire
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
Via Investor Brand Network
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
Via InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
Via InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! 
Via Benzinga
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
Via Investor Brand Network
Exposures Product Safety
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
Via Investor Brand Network
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.